Climb Bio's (CLYM) Outperform Rating Reaffirmed at Royal Bank Of Canada

Climb Bio logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Royal Bank of Canada reaffirmed its Outperform rating on Climb Bio and set a $23 price target, implying 134.26% upside from the prior close.
  • Analyst sentiment is broadly positive: MarketBeat reports a consensus Buy rating and an average price target of $28.14.
  • Climb Bio reported a quarterly loss of $0.18 per share, beating analyst estimates of a $0.20 loss by $0.02. Shares opened at $9.82 on Wednesday.
  • Five stocks we like better than Climb Bio.

Climb Bio (NASDAQ:CLYM - Get Free Report)'s stock had its "outperform" rating reiterated by stock analysts at Royal Bank Of Canada in a report issued on Wednesday, Benzinga reports. They presently have a $23.00 price target on the stock. Royal Bank Of Canada's price target indicates a potential upside of 134.26% from the stock's previous close.

CLYM has been the topic of a number of other reports. HC Wainwright reiterated a "buy" rating on shares of Climb Bio in a research report on Monday, October 12th. Oppenheimer boosted their price objective on shares of Climb Bio from $18.00 to $25.00 and gave the company an "outperform" rating in a report on Tuesday, September 8th. Guggenheim reaffirmed a "buy" rating on shares of Climb Bio in a research note on Monday, October 26th. Wedbush increased their target price on shares of Climb Bio from $25.00 to $27.00 and gave the stock an "outperform" rating in a report on Thursday, November 5th. Finally, Piper Sandler reissued an "overweight" rating on shares of Climb Bio in a research report on Tuesday, October 27th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $28.14.

View Our Latest Analysis on CLYM

Climb Bio Stock Up 0.4%

NASDAQ:CLYM opened at $9.82 on Wednesday. Climb Bio has a 12-month low of $1.63 and a 12-month high of $18.33. The firm has a market capitalization of $576.71 million, a P/E ratio of -11.99 and a beta of 0.01. The stock's fifty day simple moving average is $11.34 and its 200-day simple moving average is $10.68.

Climb Bio (NASDAQ:CLYM - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.02. As a group, equities research analysts expect that Climb Bio will post -0.75 earnings per share for the current year.

Insider Buying and Selling at Climb Bio

In other news, Director Stephen Thomas sold 100,000 shares of Climb Bio stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $13.67, for a total transaction of $1,367,000.00. Following the transaction, the director owned 467,969 shares in the company, valued at $6,397,136.23. The trade was a 17.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.60% of the stock is owned by company insiders.

Institutional Trading of Climb Bio

Hedge funds have recently bought and sold shares of the stock. Braidwell LP grew its holdings in shares of Climb Bio by 102.6% during the second quarter. Braidwell LP now owns 3,099,027 shares of the company's stock worth $40,411,000 after buying an additional 1,569,352 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Climb Bio in the 2nd quarter valued at about $30,708,000. State Street Corp raised its stake in Climb Bio by 34.7% in the 3rd quarter. State Street Corp now owns 1,850,010 shares of the company's stock valued at $21,220,000 after acquiring an additional 476,466 shares during the period. ADAR1 Capital Management LLC acquired a new stake in Climb Bio during the 2nd quarter valued at $10,727,000. Finally, Integral Health Asset Management LLC acquired a new stake in Climb Bio during the 3rd quarter valued at $8,029,000. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Climb Bio Company Profile

(Get Free Report)

Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.

Featured Articles

Analyst Recommendations for Climb Bio (NASDAQ:CLYM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Climb Bio Right Now?

Before you consider Climb Bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.

While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines